Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Nanofibrillar Ionic Polymer Composites Enable High-Modulus Ion-Conducting Membranes.

Fox RJ, Yu D, Hegde M, Kumbhar AS, Madsen LA, Dingemans TJ.

ACS Appl Mater Interfaces. 2019 Sep 30. doi: 10.1021/acsami.9b10921. [Epub ahead of print]

PMID:
31507155
2.

Vitamin D and MRI measures in progressive multiple sclerosis.

Abbatemarco JR, Fox RJ, Li H, Ontaneda D.

Mult Scler Relat Disord. 2019 Aug 13;35:276-282. doi: 10.1016/j.msard.2019.08.014. [Epub ahead of print]

PMID:
31445221
3.

An experimental test for body size-dependent effects of male harassment and an elevated copulation rate on female lifetime fecundity and offspring performance.

Iglesias-Carrasco M, Fox RJ, Vega-Trejo R, Jennions MD, Head ML.

J Evol Biol. 2019 Aug 23. doi: 10.1111/jeb.13526. [Epub ahead of print]

PMID:
31444811
4.

Understanding the Efficiency of Splenic Hemangiosarcoma Diagnosis Using Monte Carlo Simulations.

Herman EJ, Stern AW, Fox RJ, Dark MJ.

Vet Pathol. 2019 Aug 18:300985819868732. doi: 10.1177/0300985819868732. [Epub ahead of print]

PMID:
31422751
5.

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis.

Dutta R, Mahajan KR, Nakamura K, Ontaneda D, Chen J, Volsko C, Dudman J, Christie E, Dunham J, Fox RJ, Trapp BD.

J Vis Exp. 2019 Jul 19;(149). doi: 10.3791/59511.

PMID:
31380830
6.

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.

McGinley MP, Cola PA, Fox RJ, Cohen JA, Corboy JJ, Miller D.

Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314. [Epub ahead of print]

PMID:
31368401
7.

Demyelinating lesions and progressive MS: Location, location, location.

Yeh EA, Fox RJ.

Neurology. 2019 Aug 13;93(7):283-284. doi: 10.1212/WNL.0000000000007933. Epub 2019 Jul 9. No abstract available.

PMID:
31289147
8.

The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.

Chataway J, Weir CJ, Fox RJ.

Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985. [Epub ahead of print] No abstract available.

PMID:
31218918
9.

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.

Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.

BMC Neurol. 2019 Jun 8;19(1):116. doi: 10.1186/s12883-019-1337-z.

10.

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.

Marrie RA, Dufault B, Tyry T, Cutter GR, Fox RJ, Salter A.

Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722. [Epub ahead of print]

PMID:
31161917
11.

Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA.

Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836. [Epub ahead of print]

PMID:
31079537
12.

The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments.

Salter A, Fox RJ, Tyry T, Cutter G, Marrie RA.

Mult Scler Relat Disord. 2019 Jun;31:165-172. doi: 10.1016/j.msard.2019.04.014. Epub 2019 Apr 13.

PMID:
31063935
13.

Sexual selection, phenotypic plasticity and female reproductive output.

Fox RJ, Fromhage L, Jennions MD.

Philos Trans R Soc Lond B Biol Sci. 2019 Mar 18;374(1768):20180184. doi: 10.1098/rstb.2018.0184.

PMID:
30966965
14.

Beyond buying time: the role of plasticity in phenotypic adaptation to rapid environmental change.

Fox RJ, Donelson JM, Schunter C, Ravasi T, Gaitán-Espitia JD.

Philos Trans R Soc Lond B Biol Sci. 2019 Mar 18;374(1768):20180174. doi: 10.1098/rstb.2018.0174.

15.

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.

Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ.

Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27.

16.

Author response: Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2019 Mar 19;92(12):586. doi: 10.1212/WNL.0000000000007128. No abstract available.

PMID:
30886076
17.

A survey of risk tolerance to multiple sclerosis therapies.

Fox RJ, Cosenza C, Cripps L, Ford P, Mercer M, Natarajan S, Salter A, Tyry T, Cofield SS.

Neurology. 2019 Apr 2;92(14):e1634-e1642. doi: 10.1212/WNL.0000000000007245. Epub 2019 Mar 13.

18.

Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Mowry EM, Marrie RA.

Mult Scler Relat Disord. 2019 Apr;29:86-93. doi: 10.1016/j.msard.2019.01.031. Epub 2019 Jan 24.

PMID:
30690340
19.

Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA.

Neurol Clin Pract. 2018 Dec;8(6):472-481. doi: 10.1212/CPJ.0000000000000523.

PMID:
30588376
20.

C-H Arylation in the Formation of a Complex Pyrrolopyridine, the Commercial Synthesis of the Potent JAK2 Inhibitor, BMS-911543.

Fox RJ, Cuniere NL, Bakrania L, Wei C, Strotman NA, Hay M, Fanfair D, Regens C, Beutner GL, Lawler M, Lobben P, Soumeillant MC, Cohen B, Zhu K, Skliar D, Rosner T, Markwalter CE, Hsiao Y, Tran K, Eastgate MD.

J Org Chem. 2019 Apr 19;84(8):4661-4669. doi: 10.1021/acs.joc.8b02383. Epub 2018 Nov 12.

PMID:
30388009
21.

Symptomatic Vertebral Hemangioma of the Posterior Elements Sharing Blood Supply with a Radiculomedullary Artery.

Persad AR, Fox RJ, Rempel JL.

Int J Spine Surg. 2018 Aug 31;12(4):415-418. doi: 10.14444/5049. eCollection 2018 Aug.

22.

Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Baldassari LE, Fox RJ.

Drugs. 2018 Oct;78(15):1549-1566. doi: 10.1007/s40265-018-0984-5. Review.

PMID:
30255442
23.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

24.

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.

Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM, Battapady H, Mork S, Ontaneda D, Jones SE, Fox RJ, Chen J, Nakamura K, Rudick RA.

Lancet Neurol. 2018 Oct;17(10):870-884. doi: 10.1016/S1474-4422(18)30245-X. Epub 2018 Aug 22.

25.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

26.

Progressive multifocal leukoencephalopathy with extended natalizumab dosing.

Baldassari LE, Jones SE, Clifford DB, Fox RJ.

Neurol Clin Pract. 2018 Jun;8(3):e12-e14. doi: 10.1212/CPJ.0000000000000457. No abstract available.

27.

Good parenting may not increase reproductive success under environmental extremes.

Fox RJ, Head ML, Barber I.

J Evol Biol. 2018 Nov;31(11):1638-1646. doi: 10.1111/jeb.13358. Epub 2018 Aug 19.

PMID:
30063102
28.

Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial.

Zhou X, Sakaie KE, Debbins JP, Narayanan S, Fox RJ, Lowe MJ.

Magn Reson Imaging. 2018 Nov;53:105-111. doi: 10.1016/j.mri.2018.07.011. Epub 2018 Jul 23.

PMID:
30048675
29.

Prospects of siponimod in secondary progressive multiple sclerosis.

McGinley M, Fox RJ.

Ther Adv Neurol Disord. 2018 Jul 17;11:1756286418788013. doi: 10.1177/1756286418788013. eCollection 2018. No abstract available.

30.

Technical Note: Retrospective reduction in systematic differences across scanner changes by accounting for noise floor effects in diffusion tensor imaging.

Sakaie K, Zhou X, Lin J, Debbins J, Lowe M, Fox RJ.

Med Phys. 2018 Jul 11. doi: 10.1002/mp.13088. [Epub ahead of print]

PMID:
29998491
31.

Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?

Conway DS, Cecilia Vieira M, Thompson NR, Parker KN, Meng X, Fox RJ.

Mult Scler J Exp Transl Clin. 2018 May 23;4(2):2055217318777894. doi: 10.1177/2055217318777894. eCollection 2018 Apr-Jun.

32.

Temperature influences habitat preference of coral reef fishes: Will generalists become more specialised in a warming ocean?

Matis PA, Donelson JM, Bush S, Fox RJ, Booth DJ.

Glob Chang Biol. 2018 Jul;24(7):3158-3169. doi: 10.1111/gcb.14166. Epub 2018 May 20.

PMID:
29658157
33.

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2018 May 1;90(18):819-820. doi: 10.1212/WNL.0000000000005409. Epub 2018 Mar 30. No abstract available.

PMID:
29602911
34.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
35.

Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].

Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L.

Clin Ther. 2018 May;40(5):812. doi: 10.1016/j.clinthera.2018.02.005. Epub 2018 Mar 7. No abstract available.

PMID:
29523369
36.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324
37.

Strategy To Prepare 3-Bromo- and 3-Chloropyrazoles.

Fox RJ, Schmidt MA, Eastgate MD.

J Org Chem. 2018 Mar 2;83(5):2830-2839. doi: 10.1021/acs.joc.7b03282. Epub 2018 Feb 19.

PMID:
29429343
38.

Tissue Markers for Acute Multiple Sclerosis Treatment Response-A Step Toward Personalized Medicine.

Fox RJ.

JAMA Neurol. 2018 Apr 1;75(4):406-407. doi: 10.1001/jamaneurol.2017.4850. No abstract available.

PMID:
29404560
39.

'Stick with your own kind, or hang with the locals?' Implications of shoaling strategy for tropical reef fish on a range-expansion frontline.

Smith SM, Fox RJ, Booth DJ, Donelson JM.

Glob Chang Biol. 2018 Apr;24(4):1663-1672. doi: 10.1111/gcb.14016. Epub 2018 Jan 15.

PMID:
29334689
40.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
41.

Shared Decision Making and Autonomy Among US Participants with Multiple Sclerosis in the NARCOMS Registry.

Cofield SS, Thomas N, Tyry T, Fox RJ, Salter A.

Int J MS Care. 2017 Nov-Dec;19(6):303-312. doi: 10.7224/1537-2073.2016-091.

42.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

43.

Advancing trial design in progressive multiple sclerosis.

Fox RJ, Chataway J.

Mult Scler. 2017 Oct;23(12):1573-1578. doi: 10.1177/1352458517729768.

44.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584
45.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

46.

T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis.

Nakamura K, Chen JT, Ontaneda D, Fox RJ, Trapp BD.

Ann Neurol. 2017 Oct;82(4):635-639. doi: 10.1002/ana.25019. Epub 2017 Sep 21.

PMID:
28833377
47.

DNA methylation in demyelinated multiple sclerosis hippocampus.

Chomyk AM, Volsko C, Tripathi A, Deckard SA, Trapp BD, Fox RJ, Dutta R.

Sci Rep. 2017 Aug 18;7(1):8696. doi: 10.1038/s41598-017-08623-5.

48.

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.

Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL.

Neurol Ther. 2017 Dec;6(2):175-187. doi: 10.1007/s40120-017-0077-5. Epub 2017 Aug 2.

49.

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.

Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.

Clin Ther. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25.

50.

Autologous hematopoietic stem cell transplantation for MS: Safer than previously thought.

Burman J, Fox RJ.

Neurology. 2017 May 30;88(22):2072-2073. doi: 10.1212/WNL.0000000000003995. Epub 2017 Apr 28. No abstract available.

PMID:
28455384

Supplemental Content

Support Center